Communiqués Gain Therapeutics, Inc.

Actions

GANX

US36269B1052

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
1,905 ^USD	-4,75%		-6,16%	-40,84%

11/08	Gain Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
16/07	Gain Therapeutics nomme Joanne Taylor au poste de Directrice scientifique et Terenzio Ignoni en tant que Directeur des opérations	MT

Communiqués

25/08	Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference	GL
11/08	Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update	GL
16/07	Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update	GL
29/06	Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease	GL
10/06	Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit	GL
26/05	Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026	GL
26/05	Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026	AQ
11/05	Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update	GL
27/04	Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026	AQ
24/04	Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026	GL
24/04	Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026	AQ
26/03	Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update	GL
19/03	Gain Therapeutics to Present at the 38th Annual ROTH Conference	GL
18/03	Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026	GL
12/03	Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update	GL
12/03	Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update	AQ
19/02	Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference	GL
07/01	Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week	GL
06/01	Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287	GL
18/12	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease	GL
18/12	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease	AQ
18/12	Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease	GL
20/11	Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025	GL
12/11	Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update	GL
12/11	Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update	AQ